MAP2K6

Across TCGA pan-cancer cohorts, MAP2K6 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MAP2K6’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MAP2K6 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MAP2K6 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and PDAC are the cancer types where MAP2K6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP2K6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	−0.958	<.001	11	view →
COAD	All	IV	−0.931	<.001	11	view →
PDAC	Female	III,IV	−1.010	<.001	8	view →
LUAD	Female	II,III,IV	−0.465	<.001	8	view →
CCRCC	Female	All	−0.304	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MAP2K6–HNSC

Open the HNSC breakdown →